Alumis, Inc. (ALMS)
23.29
+0.26
(+1.13%)
USD |
NASDAQ |
Aug 25, 12:54
Alumis Enterprise Value : 2.494B for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 2.494B |
| August 21, 2026 | 2.640B |
| August 20, 2026 | 2.472B |
| August 19, 2026 | 2.617B |
| August 18, 2026 | 2.731B |
| August 17, 2026 | 2.811B |
| August 14, 2026 | 2.787B |
| August 13, 2026 | 2.671B |
| August 12, 2026 | 2.817B |
| August 11, 2026 | 2.794B |
| August 10, 2026 | 3.072B |
| August 07, 2026 | 3.081B |
| August 06, 2026 | 3.107B |
| August 05, 2026 | 3.019B |
| August 04, 2026 | 3.019B |
| August 03, 2026 | 2.891B |
| July 31, 2026 | 3.164B |
| July 30, 2026 | 3.254B |
| July 29, 2026 | 2.924B |
| July 28, 2026 | 3.008B |
| July 27, 2026 | 3.014B |
| July 24, 2026 | 3.132B |
| July 23, 2026 | 3.171B |
| July 22, 2026 | 3.236B |
| July 21, 2026 | 3.396B |
| Date | Value |
|---|---|
| July 20, 2026 | 3.130B |
| July 17, 2026 | 3.217B |
| July 16, 2026 | 3.033B |
| July 15, 2026 | 3.236B |
| July 14, 2026 | 3.040B |
| July 13, 2026 | 3.145B |
| July 10, 2026 | 3.172B |
| July 09, 2026 | 3.428B |
| July 08, 2026 | 3.356B |
| July 07, 2026 | 3.295B |
| July 06, 2026 | 3.038B |
| July 02, 2026 | 2.940B |
| July 01, 2026 | 2.958B |
| June 30, 2026 | 3.150B |
| June 29, 2026 | 2.966B |
| June 26, 2026 | 2.871B |
| June 25, 2026 | 2.697B |
| June 24, 2026 | 2.674B |
| June 23, 2026 | 2.631B |
| June 22, 2026 | 2.642B |
| June 18, 2026 | 2.491B |
| June 17, 2026 | 2.445B |
| June 16, 2026 | 2.352B |
| June 15, 2026 | 2.439B |
| June 12, 2026 | 2.585B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Corcept Therapeutics, Inc. | 13.00B |
| Aclaris Therapeutics, Inc. | 792.59M |
| Crinetics Pharmaceuticals, Inc. | 7.812B |
| Tarsus Pharmaceuticals, Inc. | 2.790B |
| Structure Therapeutics, Inc. | 2.154B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -142.22M |
| Revenue (Quarterly) | 1.662M |
| Total Expenses (Quarterly) | 143.88M |
| EPS Diluted (Quarterly) | -1.114 |
| Gross Profit Margin (Quarterly) | 47.41% |
| Profit Margin (Quarterly) | -8.56K% |
| Earnings Yield | -16.36% |
| Normalized Earnings Yield | -15.03 |